Preclinical data showed that SGLT2 inhibitors inhibit sodium–hydrogen exchange in cardiac myocytes, which may ameliorate myocardial hypertrophy, fibrosis, remodeling, and heart failure (Arow et al., 2020) and, therefore, lower the risk of AF. Here, SLC5A2 is linked to heart failure.